Group 1 - The company announced the use of idle funds to subscribe to notes linked to a fund issued by Essence Global Investment Limited and China Rock Fund, with a total scale of approximately HKD 400 million, aimed at enhancing capital returns and ensuring liquidity [1] - Following the announcement, the company's stock price increased by 3.76% on the first trading day (February 9), but experienced volatility in subsequent days [1] - Over the five trading days from February 9 to February 13, the stock price showed fluctuations, with a maximum range of 10.16%, indicating mixed market sentiment [1] Group 2 - According to the Q2 2025 financial report, the company recorded a quarterly revenue of approximately CNY 159 million, a quarter-on-quarter increase of 76.7%, and a net profit of CNY 52 million, with a gross margin of 84% [2] - The generic drug business accounted for 98% of the revenue, with centralized procurement products contributing significantly to the growth [2] - Although the financial report data is robust, its release in October 2025 means it has limited direct impact on the current stock price [2]
海西新药动用4亿港元认购基金票据，股价近期波动明显